Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve the Standalone and ....
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals has scheduled a Board meeting on May 29, 2026 to consider and approve the Standalone and Consolidated Audited Financial Results for Q4 and the full year ended March 31, 2026. The board will also review and recommend dividend, if any, on equity shares for FY ended March 31, 2026. The company has closed its trading window from March 31, 2026 to May 31, 2026 for directors and designated persons in compliance with SEBI Insider Trading Regulations. This is a routine quarterly/annual result announcement as per SEBI listing regulations.
This is a standard pre-result announcement notice. The stock may see volatility around May 29, 2026 when results are approved and published. Any dividend recommendation will be a key factor for investor sentiment.